We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
MRNA & MRK's Personalized Cancer Therapy Delivers Strong 5-Year Data
Read MoreHide Full Article
Key Takeaways
MRNA/MRK evaluated intismeran autogene plus Keytruda in high-risk melanoma patients post-surgery.
MRNA said intismeran autogene plus MRK's Keytruda cut recurrence or death risk by 49% after surgery.
MRNA & MRK plan to share more follow-up data on primary/secondary endpoints at future medical conferences.
Shares of Moderna (MRNA - Free Report) were up 15.8% on Jan. 21, after the company and its partner Merck (MRK - Free Report) announced positive median five-year follow-up data from a phase IIb study, which evaluated their personalized cancer therapy combo in certain patients with high-risk melanoma, a serious form of skin cancer.
The KEYNOTE-942/mRNA-4157-P201 study evaluated Moderna’s investigational mRNA-based individualized neoantigen therapy (INT), intismeran autogene (mRNA-4157 or V940), in combination with Merck’s blockbuster PD-L1 inhibitor, Keytruda (pembrolizumab), for treating patients with high-risk melanoma (stage III/IV) following complete resection.
Data from this pre-planned follow-up analysis showed that adjuvant treatment with intismeran autogene + Keytruda continued to demonstrate sustained and clinically meaningful improvement in recurrence-free survival — the primary endpoint of the study. The combo therapy reduced the risk of recurrence or death by 49% versus Keytruda alone in patients with high-risk melanoma following complete resection.
Per the company, patients suffering from stage III/IV melanoma remain at high risk of recurrence following surgery. The study demonstrating the long-term potential of intismeran autogene combined with Keytruda to lower the risk of recurrence in certain patients with melanoma marks an important milestone.
Moderna and Merck plan to share additional follow-up data on primary and secondary endpoints at an upcoming medical meeting.
This analysis from the phase IIb KEYNOTE-942/mRNA-4157-P201 study builds on the primary analysis conducted at around two years of follow-up and a subsequent analysis at three years of follow-up. The safety profile of intismeran autogene in combination with Keytruda in the study remains similar to that seen in previously reported studies.
MRNA’s Stock Price Performance
MRNA stock hit a 52-week high following the announcement of the above news. In the past six months, shares of Moderna have rallied 60.8% compared with the industry’s rise of 21.5%.
Image Source: Zacks Investment Research
MRNA’s Ongoing Development Activities With Intismeran Autogene
Intismeran autogene is an experimental, personalized mRNA-based cancer therapy that is designed using the unique genetic mutations found in a patient’s tumor and can target up to 34 tumor-specific antigens.
Besides the melanoma indication, Moderna and Merck are evaluating the therapy in two pivotal phase III studies in the non-small cell lung cancer (NSCLC) space. Moderna and Merck are also evaluating the therapy across various mid-to-late-stage studies for other cancer indications, including melanoma, bladder cancer and renal cell carcinoma. A commercial launch for this cancer therapy is targeted for next year.
Based on the success achieved with intismeran autogene, Moderna is now focusing on expanding its oncology pipeline. It is also prioritizing the development of mRNA-4359, an investigational checkpoint adaptive immune modulation therapy, currently being evaluated in early-to-mid-stage studies for first-line melanoma and first-line metastatic NSCLC. A data readout on the phase II portion of this study is expected later in 2026.
Over the past 60 days, estimates for Alkermes’ 2026 earnings per share (EPS) have increased from $1.54 to $1.90. Shares of ALKS have gained 27% over the past six months.
Alkermes’ earnings beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion, with the average surprise being 4.58%.
Over the past 60 days, Immunocore’s loss per share estimates for 2026 have decreased from 97 cents to 90 cents. Shares of IMCR have lost 4.6% over the past six months.
Immunocore’s earnings beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion, with the average surprise being 53.96%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
MRNA & MRK's Personalized Cancer Therapy Delivers Strong 5-Year Data
Key Takeaways
Shares of Moderna (MRNA - Free Report) were up 15.8% on Jan. 21, after the company and its partner Merck (MRK - Free Report) announced positive median five-year follow-up data from a phase IIb study, which evaluated their personalized cancer therapy combo in certain patients with high-risk melanoma, a serious form of skin cancer.
The KEYNOTE-942/mRNA-4157-P201 study evaluated Moderna’s investigational mRNA-based individualized neoantigen therapy (INT), intismeran autogene (mRNA-4157 or V940), in combination with Merck’s blockbuster PD-L1 inhibitor, Keytruda (pembrolizumab), for treating patients with high-risk melanoma (stage III/IV) following complete resection.
Data from this pre-planned follow-up analysis showed that adjuvant treatment with intismeran autogene + Keytruda continued to demonstrate sustained and clinically meaningful improvement in recurrence-free survival — the primary endpoint of the study. The combo therapy reduced the risk of recurrence or death by 49% versus Keytruda alone in patients with high-risk melanoma following complete resection.
Per the company, patients suffering from stage III/IV melanoma remain at high risk of recurrence following surgery. The study demonstrating the long-term potential of intismeran autogene combined with Keytruda to lower the risk of recurrence in certain patients with melanoma marks an important milestone.
Moderna and Merck plan to share additional follow-up data on primary and secondary endpoints at an upcoming medical meeting.
This analysis from the phase IIb KEYNOTE-942/mRNA-4157-P201 study builds on the primary analysis conducted at around two years of follow-up and a subsequent analysis at three years of follow-up. The safety profile of intismeran autogene in combination with Keytruda in the study remains similar to that seen in previously reported studies.
MRNA’s Stock Price Performance
MRNA stock hit a 52-week high following the announcement of the above news. In the past six months, shares of Moderna have rallied 60.8% compared with the industry’s rise of 21.5%.
Image Source: Zacks Investment Research
MRNA’s Ongoing Development Activities With Intismeran Autogene
Intismeran autogene is an experimental, personalized mRNA-based cancer therapy that is designed using the unique genetic mutations found in a patient’s tumor and can target up to 34 tumor-specific antigens.
Besides the melanoma indication, Moderna and Merck are evaluating the therapy in two pivotal phase III studies in the non-small cell lung cancer (NSCLC) space. Moderna and Merck are also evaluating the therapy across various mid-to-late-stage studies for other cancer indications, including melanoma, bladder cancer and renal cell carcinoma. A commercial launch for this cancer therapy is targeted for next year.
Based on the success achieved with intismeran autogene, Moderna is now focusing on expanding its oncology pipeline. It is also prioritizing the development of mRNA-4359, an investigational checkpoint adaptive immune modulation therapy, currently being evaluated in early-to-mid-stage studies for first-line melanoma and first-line metastatic NSCLC. A data readout on the phase II portion of this study is expected later in 2026.
Moderna, Inc. Price
Moderna, Inc. price | Moderna, Inc. Quote
MRNA’s Zacks Rank & Stocks to Consider
Moderna currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Alkermes (ALKS - Free Report) and Immunocore (IMCR - Free Report) , both sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for Alkermes’ 2026 earnings per share (EPS) have increased from $1.54 to $1.90. Shares of ALKS have gained 27% over the past six months.
Alkermes’ earnings beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion, with the average surprise being 4.58%.
Over the past 60 days, Immunocore’s loss per share estimates for 2026 have decreased from 97 cents to 90 cents. Shares of IMCR have lost 4.6% over the past six months.
Immunocore’s earnings beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion, with the average surprise being 53.96%.